Hemispherx Biopharma (HEB) Reports Q2 Loss of $0.01; Reports Implementation of Austerity Measures
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Hemispherx Biopharma Announces Financial Results for the Six Months Ended June 30, 2016
August 15, 2016 5:02 PM EDTThe company continues to focus on commercial success by seeking co-development partners and working closely with the research and regulatory communities to bring disease fighting technologies to the world.
Conference Call Scheduled for Friday, August 19, 2016 at 11:00 AM EDT
PHILADELPHIA, Aug. 15, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT: HEB) announced its financial results for the six months ended June 30, 2016. The net loss was approximately $3,467,000 or $(0.01) per share as compared to a net loss of $8,290,000 or ($0.04) per share for the same six-month period in 2015. Cash, cash equivalents and... More
